# BeiGene and Amgen form global oncology collaboration

BeiGene and Amgen announced a global strategic oncology collaboration for the commercialization and development of three Amgen drugs in China and joint development of 20 pipeline assets. Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion.

- Type: Partnership
- Announced: 2019-10-31
- Where: China, China
- Value: $2.70B
- Status: announced
- Products: XGEVA, KYPROLIS, BLINCYTO, oncology pipeline assets
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Amgen](https://endata.com/companies/21121.md) (partner)
- [BeiGene](https://endata.com/companies/43012.md) (partner)

## Sources

- [nasdaq.com](https://www.nasdaq.com/press-release/beigene-announces-global-strategic-oncology-collaboration-with-amgen-2019-10-31), 2019-10-31: "BeiGene, Ltd. and Amgen today announced a global strategic oncology collaboration for the commercialization and development in China of Amgen’s XGEVA, KYPROLIS, and BLINCYTO"

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.